Would a Japanese Atryn clinical study take around 2 to 3 years to enroll, complete, get acceptance, and gain marketing approval, with 2010 a likely target for revenue from Japan if GTCB partners within next half year? Maybe Japan can use data from the US and Europe trials.
While news of a new, major supply partnership would be great and would make GTCB more of a powerhouse, it seems that a pps rise from that news would not stay large since the market seems to be hard-nosed about revenue from approved, marketed drugs. Then again, maybe upward momentum from all of the upcoming progress will put some fire under the pps!
Market Data 
Markets 
AI
